Brokerages Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Target Price at $12.33

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $12.3333.

DMAC has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st. Lake Street Capital reiterated a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th. Cantor Fitzgerald started coverage on shares of DiaMedica Therapeutics in a report on Friday, November 14th. They issued an “overweight” rating for the company. Finally, Wall Street Zen lowered shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th.

Institutional Investors Weigh In On DiaMedica Therapeutics

Hedge funds have recently modified their holdings of the stock. Cooperman Leon G boosted its position in shares of DiaMedica Therapeutics by 98.2% in the third quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock worth $22,463,000 after buying an additional 1,619,761 shares during the period. Millennium Management LLC purchased a new position in DiaMedica Therapeutics during the 3rd quarter valued at about $8,157,000. Paragon Associates & Paragon Associates II Joint Venture increased its holdings in shares of DiaMedica Therapeutics by 34.6% in the 3rd quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after purchasing an additional 225,000 shares during the period. Geode Capital Management LLC increased its holdings in shares of DiaMedica Therapeutics by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 764,255 shares of the company’s stock valued at $6,085,000 after purchasing an additional 52,437 shares during the period. Finally, State Street Corp grew its position in DiaMedica Therapeutics by 31.7% during the fourth quarter. State Street Corp now owns 627,771 shares of the company’s stock valued at $4,997,000 after purchasing an additional 151,188 shares in the last quarter. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Trading Up 1.6%

Shares of NASDAQ:DMAC opened at $7.71 on Wednesday. The firm’s 50 day moving average is $8.21 and its two-hundred day moving average is $7.52. DiaMedica Therapeutics has a 52 week low of $3.19 and a 52 week high of $10.42. The firm has a market capitalization of $401.54 million, a P/E ratio of -10.86 and a beta of 1.09.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.